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Abstract
Aim: Patients with chronic hepatitis C virus (HCV) infection who develop hepatocellular carcinoma (HCC) soon 
after treatment with direct antiviral agents (DAA) may have been harboring hitherto hidden tumors. If this were 
true, they should have a lower sustained viral response (SVR) rate, since active HCC hampers DAA efficacy. We 
aimed to verify this hypothesis.
Methods: We included all patients who attended an HCV clinic, provided that they: (1) had no previous history of 
HCC; (2) had received at least one DAA dose; and (3) had been followed-up clinically and ultrasonographically for 
at least six months after concluding DAA. 
Results: The study population included n = 789 patients (55% males, median age 62 years). A median of 9.3 months 
(8.8-11.9) after concluding DAA, n = 19 (2.4%) patients were discovered to harbor HCC. In comparison to all others, 
patients with HCC were more commonly male (84% vs. 54%, P = 0.009), obese (47% vs. 17%, P = 0.002), and 
cirrhotic (95% vs. 35%, P < 0.001) and had less commonly achieved an SVR (68% vs. 98%, P < 0.001). Moreover, 
they had a trend for being less commonly treatment naïve (58% vs. 67%, P = 0.051). Based on multivariate analysis, 
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the independent predictors of HCC were male sex (P = 0.031), cirrhosis (P = 0.004), obesity (P = 0.006), and failure 
to achieve an SVR (P < 0.001).
Conclusion: Lack of achieving SVR is a strong independent predictor of development of HCC early after treatment of 
hepatitis C with DAA. Treatment failure should further alert clinicians to the possibility of this dreadful complication.
Keywords: Chronic hepatitis C, direct antiviral agent, sustained viral response, hepatocellular carcinoma, obesity, 
cirrhosis
INTRODUCTION
Clearance of hepatitis C virus (HCV) infection, a major health problem, is obtainable by treating infected 
patients with one of several combinations of direct antiviral agents (DAA)[1]. Today, this desirable outcome 
can be reached so predictably and safely that HCV eradication is considered by many an achievable goal 
both on a local scale and on a global scale. Indeed, in 2016, the World Health Organization launched 
a campaign that - if successful - would eliminate viral hepatitis as a major threat to global health, with 
substantial economic benefits. Most importantly, putting HCV infection under control would prevent 
over 1.2 million deaths annually[2]. For sure, DAA treatment allows curing HCV infection in patients 
with advanced liver disease, including those who had undergone curative treatments for hepatocellular 
carcinoma (HCC). 
Soon after DAA were introduced in practice, however, surprisingly high HCC incidence and/or recurrence 
rates were reported, an observation that generated alarm and dismay among clinicians[3]. In fact, among 
HCV-related complications, HCC is the most fearsome; furthermore, in the last few years, its incidence 
appears to be increasing[4]. Doubts that viral clearance by DAA might favor emergence of HCC clones by 
reducing immune pressure on HCV have been dispelled[2]: In fact, recent studies demonstrate convincingly 
that the opposite is true, i.e., DAA-induced sustained viral response (SVR) reduces the risk for de novo 
HCC[5-7]. The current interpretation is that the controversy - which has had the merit of highlighting the 
need to continue HCC surveillance in patients with cirrhosis, despite their achievement of an SVR - might 
have been generated mainly by inconsistencies and methodological limitations that flawed earlier studies[8]. 
Conceivably, among patients “cured” of HCC, so-called “recurrences” may actually represent prevalent 
tumors, whose presence is recognized only after DAA treatment is started. Could the same explanation 
apply to the apparent increase of HCC de novo diagnosed after DAA treatment? By definition, the presence 
of HCC foci should have been excluded to call these HCCs de novo; however, surveillance of HCC relies on 
ultrasonography, whose sensitivity is limited. A clue - if not definitive proof - in favor of the hypothesis that 
hidden HCC foci might have already been present when DAA were started would be to observe lower than 
expected SVR among DAA-treated patients later found to have an incident HCC, since patients with active 
HCC respond sub-optimally to DAA[9]. In the present study, we aimed to substantiate this hypothesis. 
METHODS
Patients 
The study population included a cohort of consecutively recruited patients attending an academic liver 
clinic in Northern Italy to receive interferon-free treatment for chronic hepatitis in accordance to the 
European Association for Liver Diseases (EASL) guidelines[10]. Inclusion criteria were: (1) no previous 
diagnosis of HCC; and (2) minimum follow-up after the end of treatment of 180 days. Figure 1 presents the 
flow chart of the study. 
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The main demographic and clinical features of the patients enrolled are presented in Table 1.
The direct acting antiviral agent regimens used were sofosbuvir-based in n = 370 cases (47%) and protease 
inhibitor-based in 419 cases (53%). Among the n = 12 patients who were DAA-experienced, n = 6 (50%) 
had previously failed at least one interferon-based regimen.
Disease stage was assessed in all patients either invasively, with liver biopsy (n = 22, 2.8%), or non-
invasively, with transient elastography (Fibroscan®; n = 744, 94.3%); in further few cases, a clinical diagnosis 
of liver cirrhosis was made (n = 23, 2.9%). Liver fibrosis in biopsies was staged from F0 to F4 according to 
the METAVIR staging system[11]. A liver stiffness threshold of 12.5 kPa was indicative of cirrhosis[12]. All 
patients were screened with ultrasound before starting antiviral treatment, irrespective of the presence of 
cirrhosis. 
A clinical diagnosis of cirrhosis was reached in the presence of signs of liver decompensation and/or portal 
hypertension. HCC was diagnosed according to current EASL guidelines, which require a computed 
tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI), showing typical 
hallmarks (hypervascularity in the arterial phase followed by washout in the portal or delayed phases). 
Focal lesions without typical hallmarks of HCC and those that developed in the absence of cirrhosis were 
subjected to a liver biopsy and confirmation by an expert liver pathologist[13]. 
The outcomes of antiviral therapy were defined as follows:
- SVR: HCV RNA undetectable by a sensitive real-time polymerase chain reaction (PCR)-based assay, 
performed either after 12 or 24 weeks after the end of treatment;
- relapse: presence of detectable HCV RNA at either post-treatment week 12 or post-treatment week 24, 
having HCV RNA found undetectable at the end of treatment;
- dropout: patients who did not complete treatment as scheduled; 
- lost to follow-up: patients who did not perform a Week 12 or Week 24 after the end of treatment visit, 
although they completed treatment as scheduled.
Virological methods
Circulating HCV Ribonucleic Acid (HCV-RNA) was searched with the diagnostic system of Abbott 
RealTime HCV (Abbott, Wiesbaden, Germany), which has a sensitivity cut-off of 12 UI/mL; and the 
genotyping was performed by means of Abbott RealTime HCV Genotype II (Abbott).
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Figure 1. Flow chart of the study. HCV: chronic hepatitis C virus; DAA: direct antiviral agents; HCC: hepatocellular carcinoma
Statistical analysis
Statistical analysis was performed using Stata Rel. 15.1 (StataCorp LLC, College Station TX, USA). As 
for continuous variables, the measures of centrality and dispersion of data were median and interquartile 
range, respectively, while comparisons between groups were carried out by the Mann-Whitney test. With 
regard to categorical variables, data are presented as frequencies (%), while the associations between groups 
were verified by the Fisher’s exact test or the Pearson chi square test, as appropriate. Logistic regression 
analysis was conducted to identify predictor(s) of de novo HCC among a set of independent variables. The 
threshold for statistical significance was 0.05 (two tails) for all tests used.
RESULTS
Virologic outcomes 
When analyzed with an intention-to-treat approach, SVR was 770/789 (97.6%). In detail, among the 19 
patients who did not reach a SVR, 14/19 (74%) patients had a relapse, while 5/19 (26%) did not complete 
treatment (n = 1), died before reaching the 12 week post-treatment (n = 2), or performed neither the Post-
Treatment Week 12 nor the Post-Treatment Week 24 visits (n = 2). Thus, the rate of virologic failure in this 
study was 1.8%. SVR was similar in patients who received a sofosbuvir-based regimen (359/370, 97%) vs. 
patients who received a protease inhibitor-based regimen (411/419, 98%) (P = 0.360), and in HCV-3 infected 
(98/102, 96%) vs. non-HCV-3 infected patients (672/688, 98%) (P = 0.312). There was a non-significant 
trend for lower SVR in patients with cirrhosis (273/284, 96%) vs. non-cirrhotic patients (497/505, 98%) (P = 
0.054).
Variable n  = 789
Age, years 62 (52-74)
Male:Female, n 431 (55):358 (45)
Caucasian race, n 762 (97)
Body mass indexA, kg/m2
   ≥ 30 kg/m2
25.1 (22.6-28.4)
136 (18)
Diabetes, n 112 (14)
Prediabetes, n 156 (20)
Cirrhosis, n 284 (36)
HCV Genotype, n
   HCV-1A
   HCV-1B
   HCV-2
   HCV-3
   HCV-4
   HCV-5










HCV RNA, UI/mL (× 1000)
   < 400
   400-4000






   None
   HIV






Experienced, interferon based regimens




Table 1. Main characteristics of the study population
ABody mass index missing in n  = 18/790 (2%) patients. Continuous variables are presented 
as medians (interquartile range), categorical variables as frequencies (n ) and percentages 
(%). HCV: hepatitis C virus; HIV: human immunodeficiency virus; HBV: hepatitis B virus; 
HDV: hepatitis D virus
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Development of de novo  HCC 
Along a median follow-up of 9.3 (interquartile range, 8.8-11.9) months, n = 19/789 (2.4%) patients were 
discovered to harbor HCC. The diagnosis was based on radiological criteria in 18/19 of patients (95%). 
Table 2 presents the main characteristics of these patients in comparison to all other patients.
Among patients who developed de novo HCC after antiviral therapy, 15/19 (79%) had either one or two 
nodules at the diagnosis, 3/19 (16%) had three or more nodules, and one patient had a diffuse infiltrative 
pattern (5%). Moreover, 7/19 (37%) had portal vein thrombosis (including complete or partial and 
segmental or sub-segmental thrombosis). Twelve patients (63%) fulfilled Milan Criteria[14]. 
Based on multivariate analysis, conducted having de novo HCC as dependent variable and age, male sex, 
obesity, cirrhosis, previous treatment history, and SVR as independent variables, the only independent 
predictors were male sex, obesity, cirrhosis, and SVR. The logistic regression model is summarized in Table 3.
DISCUSSION
The present study documented that, in the experience of a single center, the strongest predictor of HCC 
development following treatment of HCV infection was the lack of achieving SVR; other important pre-
treatment factors were presence of cirrhosis, male gender, and obesity. These data confirm findings in other 
clinical and experimental studies, but they also have some novel practical implications that, in our opinion, 
may be worth considering.
Variable HCC de novo  n  = 19 (2.4%) No HCC n  = 770 (97.6%) P
Age, years 68 (58-73) 62 (52-74) 0.248
Male sex, n 16 (84) 415 (54) 0.009
Caucasian race, n 19 (100) 743 (96)A 1.000
Body mass indexA, kg/m2







Either diabetes or prediabetes, n 9 (47) 259 (34) 0.226
Cirrhosis, n 18 (95) 266 (35) < 0.001
HCV-3 Genotype, n 2 (11) 100 (13) 1.000
HCV RNA, UI/mL (× 1000)







Coinfected, n 0 (0) 56 (7) 0.389
Treatment history, n
Naïve





SVR, n 13 (68) 757 (98) < 0.001
Table 2. Comparison between patients with and without de novo HCC at the end of follow-up
ABody mass index missing in n  = 18/790 (2%) patients. Continuous variables are presented as medians (interquartile range), categorical 
variables as frequencies (n ) and percentages (%). HCV: hepatitis C virus; IFN: interferon-based regimens; DAA: direct antiviral agents; 
SVR: sustained viral response
Variable Odds ratio 95%CI P
Age 1.03 0.99-1.08 0.131
Male sex 4.45 1.14-17.3 0.031
Obesity 4.68 1.55-14.1 0.006
Cirrhosis 21.1 2.68-166.1 0.004
Treatment-experienced 1.61 0.52-5.02 0.410
Failure to achieve SVR 24.2 5.76-101.8 < 0.001
Table 3. Multivariate analysis of factors associated with de novo HCC development at the end of follow-up
All dependent variables were categorical except age (n  = 771; pseudo R2 = 0.350). Codes: male sex = 1, female sex = 0; obese = 1, not 
obese = 0; cirrhosis = 1, not cirrhosis = 0; treatment experienced (either interferon-based or DAA regimens): no = 0, yes = 1; failure to 
achieve SVR: SVR achieved = 0, SVR not achieved = 1. SVR: sustained viral response; DAA: direct antiviral agents; HCC: hepatocellular 
carcinoma
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It is well known that male gender represents a risk factor to develop HCC[15], although the reasons for the 
strong gender difference in HCC remain unclear. In the Italian population, the male to female ratio of HCC 
from any cause is 2.2 to 1, similar to what is observed in other western countries. In our cohort, the male to 
female ratio was higher, 5.3 to 1, possibly reflecting in part the age-specific sex difference in the incidence 
of HCC, which peaks at a slightly younger age than the one we observed in our study population[16]. The 
highest incidence of HCC in men could be related to the higher prevalence of cirrhosis in males due to 
more rapid disease progression before age 50 years. In fact, women during their reproductive years have a 
better control of HCV replication, possibly due to estrogens, and this fact leads to less necroinflammatory 
response and less fibrosis progression[17]. Others have suggested that estrogens have a direct putative 
antifibrogenic activity, or an interference with metabolic parameters and oxidative stress[18-20]. Finally, 
higher, genetically determined expression of interleukin-6 in males may also be a factor[21]. 
Most experts would agree that cirrhosis of any etiology is the strongest predictor of HCC. In fact, cirrhosis 
can be considered a premalignant condition, independently from the underlying liver disease[22-24]. It is 
worth mentioning that we staged liver disease mainly by transient elastography; while this is consistent 
with what is recommended by current European guidelines on hepatitis C[1], consideration must be given 
to the fact that the performance of this test may be suboptimal in obese patients. Hepatocarcinogenesis 
represents a multistep process, leading to chronic liver damage through persistent inflammatory damage 
that promotes malignant transformation[25-27]. The annual risk of HCC is as high as 3% in patients with 
cirrhosis and active HCV infection[28]. Viral hepatocarcinogenesis can be due to direct or indirect 
mechanisms, and is affected by host and environmental factors, such as alcohol intake, smoking, and HBV 
or HIV co-infections, which also increase the risk of cirrhosis. Indeed, although the estimated risk of HCC 
is increased 15-20-fold among persons infected with HCV in comparison to those who are not infected, 
most of the excess risk is limited to those with advanced hepatic fibrosis or cirrhosis[29]. 
In the present study, obesity was a major independent predictor of HCC. This observation is fully 
consistent with current literature that suggests the existence of a vicious circle linking cirrhosis/fibrosis, 
HCV infection, and lipid metabolism derangement. In the obese, the inactivation of negative regulators 
of STAT-1 and STAT-3 signaling drives the development of non-alcoholic steatohepatitis and HCC, not 
only in cirrhotic patients, but also in patients with chronic hepatitis[30,31]. Moreover, there is evidence that 
HCV-infected patients are prone to develop features of metabolic syndrome (MetS), probably due to the 
fact that the replication cycle of HCV depends heavily on the pathways of lipid metabolism in hepatocytes 
and considerably alters host lipid hemostasis[32,33]. Interestingly, two large population cohort studies from 
Taiwan showed that HCV infection was strongly associated with MetS. The prevalence of MetS in these 
patients ranged from 13% to 32%; they had an aggressive and severe liver disease, developing more severe 
fibrosis than those without MetS, which contributed to cancer development[34-36]. However, MetS did not 
affect SVR achievement after DAA[37].
The major novelty of the present study lies in the strong association observed between lack of SVR and 
identification of HCC soon after concluding DAA. Overall, the rates of SVR and virologic failure in our 
cohort (97.6% and 1.8%, respectively) were comparable with what has been observed in registration 
trials[38-40] and in real-life cohorts[25,41,42]. While some authors affirmed in several retrospective studies that 
DAA increased the rate of early recurrence/occurrence of HCC, the short follow-up, the small number of 
patients, and the study design did not allow definite conclusions[3,43,44]. In contrast, multiple large cohort 
studies and meta-analyses have since demonstrated that DAA-induced SVR is associated with reduced risk 
of HCC occurrence[45-49]. 
One possible explanation for the low SVR in those who develop HCC is that it derives from the sum of 
risk factors for HCC, such as older age, high alcohol intake, more severe fibrosis, and co-infections[50-53]. 
Although the difference did not reach statistical significance, we did observe a numerically lower SVR rate 
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in cirrhotic vs. non-cirrhotic patients, which - combined with the low number of cirrhotic patients who 
develop HCC - may create a bias. However, the results logistic regression analysis strongly support the 
independence of these two variables in predicting the development of HCC (it should also be noted that 
the test is not designed to compare the relative strength of each variable in the model). 
A different way to reconcile these findings is to hypothesize that the apparent increase of HCC incidence/
recurrence rates might be due to the difficulties of identifying small HCC foci by current screening 
methods. Not surprisingly, compared to explant pathology, ultrasound is insufficiently sensitive in detecting 
HCC in obese patients[54] and obesity hampers the quality of HCC surveillance[55-57]. Thus, one may 
speculate that, especially in obese patients, what is observed as de novo HCC is in fact missed HCC, hence 
the low SVR rate among those who “develop” HCC in our cohort. Most of the DAA failures in patients with 
previous HCC diagnosis occurred among patients with active cancers, where DAA failed in almost half of 
the cases[9], possibly because HCC may serve as a sanctuary for HCV. In agreement with these findings, in a 
preliminary report from our group, we did observe unusually low SVR rates among de novo and recurrent 
HCC cases, leading us to suggest that treatment failure should be considered a clue of a yet undetected 
HCC[58,59].
We must acknowledge several limitations of our work. First, it is a single-center study, with a short follow-
up, during which - luckily enough - only a relatively small number of patients went on to develop HCC. 
Being a retrospective analysis of data generated in clinical practice, we screened our patients before and 
after DAA treatment with ultrasound, thus we are unable to provide pre-treatment data on higher level 
dynamic imaging (CT or MRI), which was performed only in the presence of suspicious focal liver lesions. 
Finally, we do not have reliable data about current and past alcohol intake in our study population, which 
are traditionally quite difficult to obtain. Nevertheless, at least in our opinion, the study conveys two 
messages worth considering: (1) given the extremely high SVR rates obtainable today in all subgroups of 
HCV infected patients, when DAA treatment fails, the possibility that the patient harbors HCC should 
come to mind; and (2) in male, obese, cirrhotic HCV-infected patients, a second level imaging technique 
should confirm that they are free of HCC before starting a DAA regimen. 
In conclusion, the present study indicates virologic failure as a strong independent predictor for de novo 
HCC identification early after treatment of hepatitis C with DAA. Clearly, all patients with cirrhosis 
regardless of SVR response should be monitored at regular six-month intervals, since cirrhosis - either in 
the presence or in the absence of HCV - is the dominant risk factor for HCC. However, lack of achieving 
SVR should further alert clinicians to the possibility of this dreadful complication, especially among HCV 
carriers who are male, obese, and cirrhotic.
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